Samuel M Hyde
Overview
Explore the profile of Samuel M Hyde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hensley S, Hu M, Bassett R, Ying A, Zafereo M, Perrier N, et al.
J Clin Endocrinol Metab
. 2024 Mar;
109(9):2256-2268.
PMID: 38441533
Context: Sporadic medullary thyroid carcinoma (sMTC) rarely occurs in childhood and no studies have specifically focused on this entity. Objective: To describe the clinical presentations and long-term outcomes of a...
2.
Johnson A, Bannon S, Farach L, Hyde S, Hashmi S, Wagner C, et al.
Eur J Haematol
. 2022 Oct;
110(1):109-116.
PMID: 36209474
Since 2003, more than 15 genes have been identified to predispose to hereditary hematologic malignancy (HHM). Although the yield of germline analysis for leukemia appears like that of solid tumors,...
3.
Shirali A, Pieterman C, Lewis M, Hyde S, Makawita S, Dasari A, et al.
CA Cancer J Clin
. 2021 Jun;
71(5):369-380.
PMID: 34061974
No abstract available.
4.
Pieterman C, Hyde S, Wu S, Landry J, Chiang Y, Christakis I, et al.
Surgery
. 2020 Jul;
169(1):175-184.
PMID: 32703679
Background: It is unclear whether genotype-negative clinical multiple endocrine neoplasia type 1 patients derive equal benefit from prospective surveillance as genotype-positive patients. Methods: In this retrospective cohort study, we compared...
5.
Romero Arenas M, Rich T, Hyde S, Busaidy N, Cote G, Hu M, et al.
Ann Surg Oncol
. 2018 Feb;
25(5):1395-1402.
PMID: 29427212
Background: No guidelines exist regarding physicians' duty to inform former patients about novel genetic tests that may be medically beneficial. Research on the feasibility and efficacy of disseminating information and...
6.
Jaber T, Hyde S, Cote G, Grubbs E, Giles W, Stevens C, et al.
J Clin Endocrinol Metab
. 2018 Feb;
103(4):1269-1272.
PMID: 29408964
Context: Germline RET K666N mutation has been described as a pathogenic mutation with low disease penetrance for medullary thyroid cancer (MTC) without other features of multiple endocrine neoplasia type 2A....
7.
Christakis I, Qiu W, Hyde S, Cote G, Grubbs E, Perrier N, et al.
Surgery
. 2017 Nov;
163(1):212-217.
PMID: 29122330
Background: The aim of this study was to investigate the genotype-phenotype relationship of pancreatic neuroendocrine tumors in patients with multiple endocrine neoplasia type 1 treated at our institution. Methods: We...
8.
Voss R, Feng L, Lee J, Perrier N, Graham P, Hyde S, et al.
J Clin Endocrinol Metab
. 2017 Jun;
102(8):2807-2813.
PMID: 28609830
Context: High-risk RET mutations (codon 634) are associated with earlier development of medullary thyroid carcinoma (MTC) and presumed increased aggressiveness compared with moderate-risk RET mutations. Objective: To determine whether high-risk...
9.
Hyde S, Cote G, Grubbs E
Endocrinol Metab Clin North Am
. 2017 May;
46(2):491-502.
PMID: 28476233
Multiple endocrine neoplasia syndromes types 1 and 2 represent well-characterized yet clinically heterogeneous hereditary conditions for which diagnostic and management recommendations exist; genetic testing for these inherited endocrinopathies is included...
10.
Xu J, Grubbs E, Waguespack S, Jimenez C, Gagel R, Sosa J, et al.
Thyroid
. 2016 Sep;
26(12):1744-1751.
PMID: 27673361
Background: Multiple endocrine neoplasia type 2 is an autosomal dominant inherited syndrome caused by activating mutations in the RET proto-oncogene. The RET DNA variant was previously reported in two isolated...